Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03342898 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 900
- Enrollment target
NCT03342898 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 900 participants.
The verdict
NCT03342898, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 900 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60 years living in country non-endemic for both dengue and YF.
Interventions
- DRUG Placebo
- BIOLOGICAL TDV
- BIOLOGICAL YF-17D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2018-02-28 |
| Est. Completion | 2019-05-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03342898
The ClinicalTrials.gov registry entry for NCT03342898 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03342898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03342898 about?
NCT03342898 is a clinical study titled "Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults". The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60 years living in country non-endemic for both dengue and YF.
What is the current status of trial NCT03342898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 900 participants. The study started on 2018-02-28. Estimated completion is 2019-05-22.
What interventions are being tested in trial NCT03342898?
The interventions under investigation include: Placebo (DRUG), TDV (BIOLOGICAL), YF-17D (BIOLOGICAL).
Who is sponsoring clinical trial NCT03342898?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.